Boston Scientific — Business Overview

What does Boston Scientific do?

Boston Scientific is a global medical device company that develops, manufactures, and sells tools used by doctors to diagnose and treat diseases without open surgery. It markets itself as a leader in "less-invasive medicine" — meaning its products help physicians treat patients through smaller incisions, natural body openings, or implantable devices rather than traditional surgery. The company sells to hospitals, clinics, outpatient facilities, and medical offices in 127 countries and has approximately 59,000 employees worldwide.

The business is organized into two reportable segments: MedSurg and Cardiovascular, each containing several focused business units.

How does Boston Scientific make money?

Boston Scientific sells physical medical devices — primarily single-use and implantable products — directly to health care providers. Revenue is generated each time a device is used in a procedure, which creates a recurring demand pattern tied to procedure volumes rather than one-time capital purchases. Major customers include hospitals, large group purchasing organizations, and hospital networks, which represent a meaningful share of net sales.

Acquisitions are a deliberate part of the revenue growth strategy. The company regularly buys smaller device companies to add new products or enter adjacent markets. A notable recent example is the announced acquisition of Penumbra, Inc. — a thrombectomy (blood clot removal) device company — for approximately $14.5 billion, expected to close in 2026. This deal would significantly expand the vascular therapy portfolio.

What market does Boston Scientific operate in?

Boston Scientific participates in the global medical device industry, a large and structurally growing market driven by aging populations, rising chronic disease rates, and the ongoing shift toward less-invasive procedures. The company touches multiple sub-markets including cardiovascular devices, endoscopy, urology, neuromodulation, oncology, and electrophysiology. The filing does not cite a single total addressable market figure, but the breadth of specialties covered — from heart rhythm disorders to kidney stones to cancer treatment — reflects exposure across some of the largest and most active areas of medical device spending.

Several secular tailwinds support the industry. Demand for less-invasive alternatives to surgery continues to grow as health systems face pressure to reduce costs and shorten recovery times. Technologies like the FARAPULSE Pulsed Field Ablation (PFA) System — a newer method to treat atrial fibrillation — are described as driving rapid conversion away from older treatment approaches, illustrating how innovation can quickly reshape procedure volumes. Headwinds include pricing pressure from managed care organizations, reimbursement rate declines, and increasing regulatory scrutiny in major markets including the U.S., Europe, and China.

Who are Boston Scientific's main competitors?

The medical device industry is populated by large global manufacturers as well as smaller single-product companies, making the competitive landscape both broad and fragmented depending on the product category. Boston Scientific competes against diversified giants that carry multiple product lines as well as niche players focused on specific conditions or procedures. In China specifically, the filing flags competition from domestic suppliers that may benefit from their local status. The company also faces indirect competition from non-device companies offering alternative therapies.

Boston Scientific's stated competitive advantages center on clinical outcomes, physician familiarity, and product breadth. The company argues its devices compete on safety, effectiveness, ease of use, and the ability to deliver economic value to health systems — not just clinical performance. The scale of its sales force and its relationships with specialist physicians (cardiologists, urologists, gastroenterologists, oncologists, and neurologists) across 127 countries are also positioned as structural advantages. The filing does not name specific competitors directly, but well-known peers in the broader medical device space include Medtronic, Abbott Laboratories, and Johnson & Johnson MedTech.

Where does Boston Scientific operate?

Boston Scientific sells products in 127 countries, with international markets representing a core part of its long-term growth strategy. Approximately 60% of its roughly 59,000 employees are located outside the United States. The company maintains direct sales organizations in its largest markets and uses third-party distributors where a direct presence is not economical or strategic.

Emerging markets are an explicit growth priority. The filing highlights expansion into countries defined internally as "emerging markets," where the company is also building local research and development teams to address both global and local product needs at lower development cost. It conducts manufacturing and research at facilities and centers of excellence located around the world, though specific country-level revenue splits are not provided in this section.

Regulatory and geopolitical exposure in China is specifically flagged. China is called out by name as a market where domestic competitors may have an advantage, and where cost-containment initiatives could limit pricing or reimbursement levels for Boston Scientific's products. Europe also carries regulatory transition risk, as the company is working to comply with the EU's updated Medical Device Regulation (MDR), which requires significant ongoing investment through 2027–2028.